ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

ABSTRACT: Abstract

BACKGROUND

Standard of care for glioblastoma multiforme (GBM) is surgical resection followed by temozolamide, with Avastin given at relapse. Responses to Avastin remain brief; resistance may involve overexpression of Fatty Acid Synthase (FASN). Our institution is conducting a phase 2 study of Avastin with or without the FASN inhibitor TVB-2640 in patients with GBM in first relapse.

METHODS

This is a prospective, randomized, phase 2 study of Avastin with or without TVB-2640 in patients with GBM in first relapse. Primary end point is progression free survival (PFS). Inclusion criteria are: age 18, ECOG 0 to 2, GBM progression following standard combined modality treatment. Randomization is into 2 separate arms. Patients in arm 1 receive Avastin every 2 weeks in com

SUBMITTER: Konkel B 

PROVIDER: S-EPMC6216181 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature